sentence: The 26-week SHINE study was designed to determine if QVA149 met the “ combination rule ” , ie , that it was superior to its monocomponents , indacaterol and glycopyrronium ; in addition , the study had placebo and active-control ( open-label tiotropium once daily ) arms.32 Trough FEV at week 26 ( primary efficacy endpoint ) was significantly improved with QVA149 compared with the monocomponents indacaterol , glycopyrronium , and tiotropium ( Table 4 and Figure 2A ) .